DSM appoints Manja Bouman Ph.D. as President and Business Unit Director of biopharm businesses at DSM Pharmaceutical Products
Parsippany NJ, US, 22 Oct 2013 18:00 CEST
Ms. Bouman has a Ph.D. in Biochemistry from the State University of New York at Buffalo, School of Medicine & Biomedical Sciences, and held post-doctoral positions there and in Nijmegen, the Netherlands, before joining DSM Gist-Brocades in 1997. In this role Dr. Bouman was responsible for New Business Development and Licensing & Technology moving to Kiadis Pharma B.V. as Chief Executive Officer in 2004. Dr. Bouman was most recently CEO of Regenesance B.V.
With operations in Groningen, the Netherlands and in Brisbane, Australia, DSM Biologics specializes in preclinical through commercial biomanufacturing of recombinant proteins and monoclonal antibodies based on mammalian cell cultures. Dr. Bouman also heads DSM BioSolutions which offers large-scale fermentation for large and small molecule active pharmaceutical ingredients for therapeutic proteins and enzymes at DSM’s Capua, Italy site, with support from the DSM Biotechnology Center in Delft, the Netherlands.
DSM Biologics also licenses DSM’s proprietary suite of biomanufacturing technologies including XD® process technology for increasing cell density yields; RHOBUST® direct protein capture technology that combines clarification and product capture into a single step; and the Kremer Method™, an innovative approach to consolidating downstream steps into a more efficient process.